Skip to main navigation
Cyclacel
  • About
    • Company Overview
    • Research and Development Pipeline
    • People
      • Management Team
      • Board of Directors
      • Scientific Advisory Team
    • Alliances and Collaborations
  • Research & Development
    • Programs
      • Oncology Programs
        • Sapacitabine (CYC682)
        • Seliciclib (CYC202)
        • CYC116 Aurora Kinase & VEGFR2 Inhibitor
      • Other Programs
    • Science and Technology
      • Cell Cycle in Cancer
      • Drug Discovery & Development Approach
    • Clinical Trials
    • Publications
  • Investors & Media

    Investor Relations

    • Corporate Governance
      • Board of Directors
      • Committee Composition
      • Management Team
    • Common Stock Information
    • News
    • SEC Filings
    • Analysts
    • Presentations & Events
    • Corporate Factsheet
    • Annual Reports
      • Archive
    • Request Investor Pack
    • Alerting Service
  • Careers
  • Contact
Home Investors & Media Third Quarter 2019 Financial Results
Investors & Media
<< Back

Corporate Presentations & Events

Third Quarter 2019 Financial Results
11/13/19
4:30 PM EST
Listen to Webcast
Investors & Media

Investors & Media

Investor Relations

  • Corporate Governance
    • Board of Directors
    • Committee Composition
    • Management Team
  • Common Stock Information
  • News
  • SEC Filings
  • Analysts
  • Presentations & Events
  • Corporate Factsheet
  • Annual Reports
    • Archive
  • Request Investor Pack
  • Alerting Service

Investor Tools

  • Email Alerts
  • Download Library
  • RSS News Feeds
  • Print Page
  • Share This
Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter

Website created by Princeton Internet Group (PING)
Sitemap | Privacy | Disclaimer | Contact Us | Alerting Service
Copyright © 2021 Cyclacel